

1 **Comparison of the reactogenicity and immunogenicity of a reduced and standard booster**
2 **dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated**
3 **vaccine.**

4
5 Sitthichai Kanokudom^{a,b}, Suvichada Assawakosri^{a,b}, Nungruthai Suntronwong^a, Jira
6 Chansaenroj^a, Chompoonut Auphimai^a, Pornjarim Nilyanimit^a, Preeyaporn Vichaiwattana^a,
7 Thanunrat Thongmee^a, Ritthideach Yorsaeng^a, Thaneeya Duangchinda^c, Warangkana Chantima
8 ^{d,e}, Pattarakul Pakchotanon^c, Donchida Srimuan^a, Thaksaporn Thatsanatorn^a, Sirapa Klinfueng
9 ^a, Juthathip Mongkolsapaya^{f,g}, Natthinee Sudhinaraset^a, Nasamon Wanlapakorn^a, Sittisak
10 Honsawek^{b,*} and Yong Poovorawan^{a,h,*}

11 a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
12 Bangkok 10330, Thailand.

13 b Department of Biochemistry, Osteoarthritis and Musculoskeleton Research Unit, Faculty of
14 Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red
15 Cross Society, Bangkok 10330, Thailand.

16 c Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
17 Engineering and Biotechnology, National Science and Development Agency, NSTDA,
18 Pathum Thani 12120, Thailand.

19 d Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital,
20 Mahidol University, Bangkok 10700, Thailand.

21 e Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of
22 Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

23 f Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
24 Oxford, Oxford, OX3 7BN, UK.

25 g Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford,
26 Oxford, UK.

27 h The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

28

29 *Correspondence: Sittisak.h@chula.ac.th (S.H.); yong.p@chula.ac.th (Y.P.); Tel.: +662-256-
30 4452 (S.H.); +662-256-4929 (Y.P.)

31

32 **Highlights:**

- 33 • The 15 µg- and 30 µg-BNT162b2, and 50 µg- and 100 µg-mRNA-1273 booster doses
34 were compared
- 35 • Booster vaccination with the mRNA vaccine elicits high Ig and IgG anti-RBD in
36 CoronaVac-vaccinated adults
- 37 • No differences were observed in antibody responses after the reduced or standard booster
38 dose of the mRNA vaccine in CoronaVac-vaccinated adults
- 39 • Neutralizing antibodies against the delta and omicron variants were significantly higher
40 after the booster dose
- 41 • Neutralizing antibody titers were lower against the omicron variant than the delta variant
42 in all vaccinated adults

43 **Abstract:** The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare
44 problem worldwide since December 2019. The third dose of heterologous vaccine was recently
45 approved by World Health Organization. The present study compared the reactogenicity and
46 immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-
47 1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results
48 showed that headache, joint pain, and diarrhea were more frequent in the 15 µg- than the 30 µg-
49 BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 µg- than the 50
50 µg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These
51 findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses
52 against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose.
53 The reduced dose could be used to increase vaccine coverage in situations of limited global
54 vaccine supply.

55 **Keywords:** COVID-19; delta; omicron; booster; third dose; inactivated vaccine; mRNA vaccine;
56 standard dose; reduced dose; clinical trial.

57 **1. Background**

58 A shortage of the coronavirus disease 2019 (COVID-19) vaccine has been reported in
59 several countries [2]. Vaccine importing countries, including Thailand, are affected by vaccine
60 shortage, resulting in delays in the vaccination schedule. A dose reduction strategy can help
61 countries to save costs on the imported vaccine and distribute vaccine more quickly during the
62 COVID-19 outbreak. Several countries achieved high two-dose COVID-19 vaccination coverage
63 but have been unable to control the spread of SARS-CoV-2. The delta and omicron variants have
64 recently spread worldwide [3], and are causing breakthrough infection in vaccinated individuals
65 [4, 5]. A preliminary study showed that vaccination of inactivated vaccine-vaccinated adults with
66 a 15 µg-BNT162b2 mRNA dose elicited high immune responses against the SARS-CoV-2 delta
67 variant [6, 7]. Our previous study demonstrated that individuals who received inactivated
68 vaccines as their primary series achieved a high immune response against delta and omicron
69 variants following receipt of a booster vaccination with the standard dose of BNT162b2 or
70 mRNA-1273 [1]. However, it remains unclear whether a half-dose booster of an mRNA vaccine,
71 especially a 50 µg-mRNA-1273 vaccination following the inactivated vaccine primary series,
72 could induce adequate neutralization of the SARS-CoV-2 delta and omicron variants. Our study
73 compared the reactogenicity and immunogenicity of reduced and standard doses of the
74 BNT162b2 and mRNA-1273 vaccines in CoronaVac (CV)-vaccinated individuals.

75

76 **2. Materials and methods**

77 2.1. Study Design

78 This prospective cohort study enrolled healthy Thai adults ≥ 18 years of age without
79 previous COVID-19 infection by medical interview at the time of enrollment. Adults who were
80 immunized with the two-dose CV 6 months (± 1 month) after the second dose and consented to
81 receive the 15 µg- BNT162b2 (n=59) or 50 µg-mRNA-1273 (n=51) reduced dose of the mRNA
82 COVID-19 vaccine booster between November to December 2021 were included in the study.
83 The comparison group included individuals who received the standard dose of either BNT162b2
84 (Pfizer-BioNTech Inc., NY) (n=54) or mRNA-1273 (Moderna Inc., Cambridge, MA) (n=58) for
85 a previous study conducted between September and December 2021 [1]. The study protocol was
86 approved by the Institutional Review Board (IRB) in the Faculty of Medicine at Chulalongkorn
87 University (IRB690/64). This trial was included on the Thai Clinical Trials Registry (TCTR

88 20210910002). Written informed consent was obtained from participants prior to enrollment.
89 The study was conducted according to the Declaration of Helsinki and the principle of Good
90 Clinical Practice Guidelines (ICH-GCP). Blood samples were collected before vaccination (V1,
91 day 0, baseline) and after receipt of the booster dose (V2, the second visit day 14 ± 7 and V3, the
92 third visit, day 28 ± 7) (Supplementary Figure S1).

93 2.2. Vaccines

94 The BNT162b (Pfizer-BioNTech Inc., New York, NY) contains 15 μg (reduced) or 30 μg
95 (standard) of mRNA encoding SARS-CoV2 spike (S) protein [8]. The mRNA-1273 (Moderna
96 Inc., Cambridge, MA) contains 50 μg (reduced) or 100 μg (standard) of mRNA encoding SARS-
97 CoV2 S protein [9].

98 2.3. Reactogenicity Assessment

99 The subjects were continuously monitored for local, systemic, and any adverse events
100 (AEs) following immunization (AEFIs) occurring within 7 days using an online or paper-based
101 self-assessment questionnaire. The data collection protocol was given to participants by trained
102 investigators during the initial visit.

103 2.4. Laboratory Measurements

104 Serum samples were collected for analysis of total immunoglobulin (Ig) specific to the
105 receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, the IgG anti-RBD, the IgG
106 anti nucleoprotein (anti-N), the neutralization assay against delta (B.1.617.2) and omicron
107 (B.1.1.529/BA.1) variants using surrogate virus neutralization test (sVNT), and the 50% focus
108 reduction neutralization test (FRNT₅₀) as previously described [1, 10]. The seropositivity rate of
109 sVNT showed $> 30\%$ inhibition, and the seropositivity rate of FRNT₅₀ was > 20 -serum dilution.
110 The assay used to measure the interferon-gamma (IFN- γ) SARS-CoV-2 releasing T cell response
111 was performed on a heparinized whole blood sample as previously described [10].

112 2.5. Statistical Analysis

113 The sample size was calculated using G*power software version 3.1.9.6 (based on
114 conventional effect size = 0.25, given significance level (α) = 0.05, power ($1-\beta$) = 0.8, numerator
115 degree of freedom = 3, and number of groups = 4). The graphical representation and statistical

116 analyses were carried out using GraphPad Prism version 9.3.1. Categorical analyses of age and
117 sex were performed using the Chi-square test. Adverse events were analyzed using the risk
118 difference with a 95% confidence interval (CI). IgG-specific RBDs and FRNT₅₀ were designated
119 as geometric mean titers (GMT) with a 95% CI. Other parameters were presented as medians
120 with interquartile ranges. The differences in antibody titers, S/C, and percentage inhibition and
121 IU/mL minus nil between groups were calculated using the Kruskal–Wallis or Wilcoxon signed-
122 rank test (non-parametric) with multiple comparison adjustments. A *p*-value of <0.05 was
123 considered statistically significant.

124

125 **3. Results**

126 3.1. Demographic data

127 A total of 222 healthy participants were analyzed, including 110 participants enrolled to
128 receive the reduced vaccine dose and 112 participants who received the standard vaccine dose
129 and were enrolled in a prior study in September 2021 [1]. The baseline demographic
130 characteristics of participants in all four groups who received reduced or standard doses of the
131 BNT162b2 or mRNA-1273 vaccines were generally comparable (Table 1). The mean age of
132 participants who received the 15 µg-BNT162b2, 30 µg-BNT162b2, 50 µg-mRNA-1273, or 100
133 µg-mRNA-1273 vaccines were 39.1 ± 10.0 , 41.6 ± 10.1 , 38.7 ± 11.1 , and 37.0 ± 10.5 years,
134 respectively. No significant differences in age and sex were observed between the groups.
135 Underlying diseases of the enrolled participants included allergy, diabetes mellitus, dyslipidemia,
136 hypertension, thyroid, and other inactive diseases (Table 1). The median days to follow-up for
137 the second visit were 18.55 (14–21), 14.3 (13–21), 15.5 (14–21), and 16 (14–20) days for the 15
138 µg-BNT162b2, 30 µg-BNT162b2, 50 µg-mRNA-1273, and 100 µg-mRNA-1273, respectively.
139 The median days to follow-up for the second visit were 28.6 (27–30), 28.3 (27–35), 28.1 (28–
140 29), and 27.9 (22–35) days for the 15 µg-BNT162b2, 30 µg-BNT162b2, 50 µg-mRNA-1273, and
141 100 µg-mRNA-1273, respectively.

142 3.2. Reactogenicity data

143 The most common solicited AE for all groups was injection site pain. Systemic events,
144 including headache and myalgia. headache, joint pain, and diarrhea were more frequent in the 15
145 µg- than the 30 µg-BNT162b2 group, while joint pain and chilling were more frequent in the 100

146 μg - than the 50 μg -mRNA-1273 group (Figure 1 and Supplementary Figure S2). No severe AEs
147 were reported.

148 3.3. Ig Anti-N, total Ig, and IgG anti-RBD responses

149 Most participants were IgG anti-N seronegative (>94%) after receiving the mRNA
150 vaccines (Supplementary Figure S3 and Table S1). There were no significant differences in the
151 GMTs of total Ig and IgG anti-RBD between the four groups at baseline. By the second visit
152 post-vaccination with 15 μg -BNT162b2, 30 μg -BNT162b2, 50 μg -mRNA-1273, and 100 μg -
153 mRNA-1273, total Ig anti-RBD levels were 28,413, 31,793, 41,171, and 51,979 U/mL,
154 respectively. By the third visit, total Ig anti-RBD was slightly reduced to 21,299, 21,053, 27,282,
155 and 33,519 U/mL, respectively (Figure 2A). Moreover, the IgG anti-RBD levels were consistent
156 with Ig anti-RBD (Figure 2B). These results indicated that there were no significant differences
157 in Ig and IgG anti-RBD levels between reduced and standard doses of the same vaccine.

158 3.4. Neutralizing antibody against the SARS-CoV-2 delta and omicron variants

159 The sVNT against the delta and omicron variants was evaluated in a subgroup of
160 participants. Seropositivity on the first visit was 3/40 (0.08%) and 1/40 (0.03%) to the delta and
161 omicron variants, respectively. By the third visit, the sera of participants from all four groups
162 achieved over 97% inhibition against the delta variant. In contrast, inhibition against the omicron
163 variant at the third visit was 71.2%, 53.5%, 61.1%, and 76.7% in the 15 μg -BNT162b2, 30 μg -
164 BNT162b2, 50 μg -mRNA-1273, and 100 μg -mRNA-1273 groups, respectively (Figure 3 and
165 Supplementary Table S1). Inhibition against the omicron variant was significantly lower among
166 participants in the 30 μg -BNT162b2 group than participants in the other groups ($p<0.05$) (Figure
167 3A).

168 To assess live virus neutralization to the delta and omicron variants, FRNT₅₀ was
169 performed. On the first visit, most participants were seronegative for FRNT₅₀ against the delta
170 and omicron variants. By the third visit, the GMT against the delta variant in the 15 μg -
171 BNT162b2 and 50 μg -mRNA-1273 groups increased to 1,505 and 2,088, respectively. The GMT
172 against omicron in the 15 μg -BNT162b2 and 50 μg -mRNA-1273 groups was 343.4 and 541.2,
173 respectively. Consistent with Ig RBD, no significant difference in FRNT₅₀ was observed in sera
174 from the reduced and standard-dose groups of the BNT162b2 and mRNA-1273 vaccines (Figure
175 3B and Supplementary Table S1).

176 3.5. QuantiFERON assay

177 The T-cell response was compared between the reduced and standard doses of the mRNA
178 vaccines in participants who previously received the two-dose CoronaVac. Results showed that
179 the median IFN- γ CD4+ T cell and CD4+ CD8+ T cell counts were higher at the second visit
180 than at baseline in all groups. By the third visit, IFN- γ CD4+ and CD4+ CD8+ T cell counts
181 were slightly reduced but this was not statistically significant. Importantly, there were no
182 differences in T cell counts between participants receiving the reduced and standard doses of
183 each vaccine (Figure 4A-B).

184

185 4. Discussion and conclusion

186 This study compared the reactogenicity and immunogenicity of the reduced and standard
187 doses of the mRNA vaccine booster in individuals who previously received a two-dose CV. A
188 few participants had detectable IgG anti-N at baseline because they had received the two-dose
189 CV. In agreement with Ig and IgG RBD responses, the reduced and standard-dose mRNA
190 booster elicited high neutralizing activity against the SAR-CoV-2 delta and omicron variants.
191 These results are consistent with a previous study of BNT162b2 following CV after three months
192 [6]. Previous studies assessing the use of the standard mRNA vaccine dose after the CV series [1,
193 7] or three standard doses of BNT162b2 or mRNA-1273 [11] also demonstrated high
194 neutralizing antibodies against the omicron variant. This aligns with another study reporting that
195 the use of 15- μ g-BNT162b2 as a booster dose elicited neutralizing activity against the SARs-
196 CoV-2 delta and omicron variants [7]. Nevertheless, a previous study of mRNA-1273 showed
197 that a third standard dose (100 μ g) elicited a stronger immune response than a third reduced dose
198 (50 μ g) [12]. However, the reduced 50 μ g-mRNA-1273 vaccine was able to elicit an immune
199 response against the SARS-CoV-2 delta and omicron variants [12-13].

200 In the present study, IFN- γ release was observed by the second visit in participants who
201 received the reduced mRNA vaccine dose. These results are consistent with previous studies of
202 response to booster vaccination with the standard dose of mRNA vaccine after 3 [10] and 6
203 months [1] of CV priming. Both BNT162b2 and mRNA-1273 vaccines are able to stimulate
204 robust antigen-specific T-cell responses after 7 days [14]. Indeed, BNT162b2 vaccination-

205 induces T-cell responses, including induction of IFN- γ , TNF- α , and IL-2, and protection against
206 ancestral strains might contribute to cross-protection against the omicron variant [15].

207 This study had some limitations. The surrogate virus neutralization test against the delta
208 variant reached the upper limit of >97% inhibition. However, the FRNT₅₀ result could explain
209 why there were no significant differences in neutralizing activity against the delta and omicron
210 variants. In addition, this study partially relied on subjects who received standard-dose
211 immunization in another study. A more recent report of the standard-dose regimen should be
212 used as the comparison group for the reduced-dose regimen. A follow-up study is underway to
213 determine the durability of the booster vaccine.

214 In conclusion, there were no significant differences between administration of the
215 reduced and standard doses of mRNA COVID-19 vaccine in participants who previously
216 received inactivated CV vaccine. This study may inform decision-making regarding the use of
217 reduced mRNA vaccine doses in healthy adults who were immunized with CV.

218

219 **Acknowledgments**

220 We would like to thank all Center of Excellence in Clinical Virology personnel and all
221 participants for helping and supporting this project. This research was financially supported by
222 the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT),
223 the Center of Excellence in Clinical Virology, Chulalongkorn University, and King
224 Chulalongkorn Memorial Hospital, and partially supported by the Second Century Fund (C2F) of
225 Sitthichai Kanokudom, Chulalongkorn University.

226 **Author Contributions:** Conceptualization: S.K. (Sitthichai Kanokudom), P.N., S.H. and Y.P.;
227 data collection:, D.S., R.Y. and T.T. (Thaksaporn Thatsanatorn); formal analysis: S.K. (Sitthichai
228 Kanokudom); Investigation: S.K. (Sitthichai Kanokudom), N.S. (Natthinee Sudhinaraset), N.W.
229 and Y.P.; methodology: S.K. (Sitthichai Kanokudom), S.A., N.S. (Nungruthai Suntronwong),
230 J.C., C.A. , T.T. (Thanunrat Thongmee), S.K. (Sirapa Klinfueng), T.D., W.C., P.P., P.V., and
231 J.M.; project administration: Y.P.; writing—original draft: S.K.(Sitthichai Kanokudom), N.W.,
232 S.H. and Y.P.; writing—review and editing: S.K. (Sitthichai Kanokudom), N.W., S.H. and Y.P.
233 All authors have read and agreed to the published version of the manuscript.

234 **Funding:** This research was financially supported by Health Systems Research Institute (HSRI),
235 National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology,
236 Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported
237 by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.

238 **Institutional Review Board Statement:** The study protocol was approved by the Institutional
239 Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 690/64).

240 **Informed Consent Statement:** Informed consent was obtained before participant enrollment.
241 The study was conducted according to the Declaration of Helsinki and the Good Clinical Practice
242 Guidelines (ICH-GCP) principles.

243 **Data Availability Statement:** The datasets generated and analyzed during the current study are
244 available from the corresponding author on reasonable request.

245 **Conflicts of Interest:** The authors declare no conflict of interest.

246 **References**

- 247 [1] Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
248 al., Neutralizing activities against the omicron variant after a heterologous booster in healthy
249 adults Receiving Two Doses of CoronaVac Vaccination. medRxiv 2022.
250 <https://doi.org/10.1101/2022.01.28.22269986>.
- 251 [2] Henn W, Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and
252 necessary measures for global immunity. *Vaccine* 2020;38(34): p.5396-5397.
253 <https://doi.org/10.1016/j.vaccine.2020.06.058>.
- 254 [3] Wang C and Han J, Will the COVID-19 pandemic end with the delta and omicron variants?
255 *Environmental Chemistry Letters* 2022; 1-17. <https://doi.org/10.1007/s10311-021-01369-7>.
- 256 [4] Kuhlmann C., Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al., Breakthrough
257 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. *Lancet*
258 2022;399(10325): p.625-626. [https://doi.org/10.1016/S0140-6736\(22\)00090-3](https://doi.org/10.1016/S0140-6736(22)00090-3).
- 259 [5] Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, et al., Severe breakthrough
260 COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. *Lancet Microbe* 2022;3(1):
261 p.e4-e5. [https://doi.org/10.1016/S2666-5247\(21\)00306-2](https://doi.org/10.1016/S2666-5247(21)00306-2).
- 262 [6] Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S,
263 Mahasirimongkol S, et al., Immunogenicity and safety of an intradermal BNT162b2 mRNA
264 vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population.
265 *Vaccines (Basel)* 2021; 9(12): 1375. <https://doi.org/10.3390/vaccines9121375>.
- 266 [7] Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, et
267 al., The immunogenicity against variants of concern and reactogenicity of four COVID-19
268 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series. medRxiv 2022.
269 <https://doi.org/10.1101/2021.11.29.21266947>.
- 270 [8] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al., Safety and efficacy
271 of the BNT162b2 mRNA Covid-19 vaccine. 2020; 383(27): p. 2603-2615.
272 <https://doi.org/10.1056/NEJMoa2034577>.
- 273 [9] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al., An mRNA
274 vaccine against SARS-CoV-2 — Preliminary Report. *N Engl J Med* 2020; 383(20): p.1920-1931.
275 <https://doi.org/10.1056/NEJMoa2022483>.
- 276 [10] Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana V, et
277 al., Safety and immunogenicity of the third booster dose with inactivated, viral vector, and

- 278 mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. *Vaccines*
279 (Basel) 2022; 10(1): 86. <https://doi.org/10.3390/vaccines10010086>.
- 280 [11] Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al, mRNA-
281 based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron
282 variant. *Cell* 2022; 185(3): 457-466.e4. <https://doi.org/10.1016/j.cell.2021.12.033>.
- 283 [12] Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, et al., SARS-CoV-2
284 Omicron variant neutralization after mRNA-1273 booster vaccination. *N Engl J Med* 2022.
285 <https://doi.org/10.1056/NEJMc2119912>.
- 286 [13] Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, et al., Safety and immunogenicity of
287 SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med*
288 2021; 27(11): p. 2025-2031. <https://doi.org/10.1038/s41591-021-01527-y>.
- 289 [14] Li, N.L., P.T. Coates, and B.H. Rovin, COVID-19 vaccination followed by activation of
290 glomerular diseases: does association equal causation? *Kidney int* 2021; 100(5): p. 959-965.
291 <https://doi.org/10.1016/j.kint.2021.09.002>.
- 292 [15] Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, Humbert M, et al., Ancestral SARS-
293 CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med* 2022
294 <https://doi.org/10.1038/s41591-022-01700-x>.

295 **Figure and Table Legends**


296 **Table 1.** Demographics and characteristics of the vaccinated cohorts

	<i>BNT162b2</i> (15 µg)	<i>BNT162b2</i> (30 µg) ^y	<i>mRNA-1273</i> (50 µg)	<i>mRNA-1273</i> (100 µg) ^y
Total number (n)	59	54	51	58
Mean age ± SD (years)	39.1±10.0	41.6±10.1	38.7±11.1	37.0±10.5
Sex				
Male (%)	28 (47.5%)	32 (59.3%)	22 (43.1%)	28 (47.8%)
Female (%)	31 (52.5%)	22 (40.7%)	29 (56.8%)	30 (52.2%)
Underlying disease (%)				
Allergy	4 (6.8%)	4 (7.4%)	5 (9.8%)	4 (6.9%)
Diabetes Mellitus	3 (5.1%)	2 (3.7%)	-	2 (3.4%)
Dyslipidemia	3 (5.1%)	4 (7.4%)	-	1 (1.7%)
Hypertension	5 (8.5%)	6 (11.1%)	3 (5.8%)	4 (6.9%)
Thyroid	1 (1.7%)	2 (3.7%)	1 (1.9%)	1 (1.7%)
Others †	2 (3.4%)	3 (5.6%)	3 (5.8%)	2 (3.4%)
Follow-up				
Second visit (two weeks)				
Mean (range) days	18.5 (14-21)	14.3 (13-21)	15.5 (14-21)	16 (14-20)
Lost to follow-up (n)	3	1	1	0
Third visit (four weeks)				
Mean (range) days	28.6 (27-30)	28.3 (27-35)	28.1 (28-29)	27.9 (22-35)
Lost to follow-up (n)	3	0	5	2

297 † Inactive disease—no medication involving immunosuppressant. ^y Previous enrolled
 298 participants of standard dose vaccination [1].


A

BNT162b2



B


mRNA-1273




299

300

301 **Figure 1.** Reactogenicity data and risk difference analysis. The recorded incidence of AEs in
 302 participants who received the reduced booster dose with A) 15 µg (reduced) or 30 µg (standard)
 303 of BNT162b2 and B) 50 µg (reduced) or 100 µg (standard) of mRNA-1273. The risk difference
 304 with 95% CI is shown.




305
306 **Figure 2.** Antibody responses against SARS-CoV-2. A) Total immunoglobulin anti-RBD
307 (U/mL) and B) IgG anti-RBD (BAU/mL). Serum was obtained from participants who received
308 two completed doses of the inactivated vaccine, CoronaVac, followed by 15 µg (reduced) mRNA
309 vaccine–BNT162b2, 30 µg (standard) mRNA vaccine–BNT162b2, 50 µg (reduced) mRNA-
310 1273, or 100 µg (standard) mRNA-1273. Lines represent GMTs (95% CI); ns indicate no
311 significant difference.



312

313 **Figure 3.** Neutralization assay against the SARS-CoV-2 delta (B.1.617.2) and omicron
314 (B.1.1.529) variants. Serum samples were obtained from participants who received two
315 completed doses of the inactivated vaccine, CoronaVac, followed by 15 µg (reduced) mRNA
316 vaccine–BNT162b2, 30 µg (standard) mRNA vaccine–BNT162b2, 50 µg (reduced) mRNA-
317 1273, or 100 µg (standard) mRNA-1273. A) Surrogate virus neutralization assay (sVNT); lines
318 represent median (interquartile range). B) Focus reduction neutralization assay (FRNT₅₀); lines
319 represent GMTs (95% CI); ns indicates no significant difference; p<0.05 (*).

320



321

322 **Figure 4. QuantiFERON SARS-CoV-2-stimulating interferon-gamma assay.** Heparinized
323 samples were immediately incubated in a QuantiFERON (QFN) blood collection tube for 21 h.
324 The plasma was evaluated using QFN IFN- γ ELISA. A) IFN- γ was produced by CD4-specific
325 Ag. B) IFN- γ was produced by CD4- and CD8-specific Ag2. Lines represent medians (IQR); ns
326 indicate no significant difference.

327 **Supplementary information**

328 **Supplementary Figure S1.** Participant flow diagram. The cohorts were primed with the primary
329 series of CV and received a reduced dose (experimental group) or standard dose (comparative
330 group) of the mRNA vaccine.

331 **Supplementary Figure S2.** Reactogenicity after receiving mRNA vaccine for 7 days post-
332 vaccination. The participants received two completed doses of the inactivated vaccine,
333 CoronaVac, followed by A) 15 µg-BNT162b2, B) 30 µg-BNT162b2, C) 50 µg-mRNA-1273, or
334 D) 100 µg-mRNA-1273. Participant percentages are shown on the Y-axis. Swelling and redness
335 were graded by measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and
336 severe (\geq 10 cm). Fever was defined as mild (38.0-38.5 °C), moderate (38.5-39.0 °C), and severe
337 (39.0 °C). Local and systemic symptoms were graded as mild (easily tolerated with no limitation
338 on regular activity), moderate (some limitation of daily activity), and severe (unable to perform
339 the regular daily activity).

340 **Supplementary Figure S3.** IgG anti nucleoprotein (N) of SARS-CoV-2 index (S/C). Serum
341 samples were obtained from participants who received two completed doses of the inactivated
342 vaccine, CoronaVac, followed by 15 µg (reduced) mRNA vaccine–BNT162b2, 30 µg (standard)
343 mRNA vaccine–BNT162b2, 50 µg (reduced) mRNA-1273, or 100 µg (standard) mRNA-1273.
344 Lines represent the median (interquartile range).

345 **Supplementary Table S1.** Patient serum responses during study trials.